|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Myocardial reperfusion injury and oxidative stress: Therapeutic opportunities显示文摘Acute myocardial infarction(AMI) is the leading cause of death worldwide. Its associated mortality, morbidity and complications have significantly decreased with the development of interventional cardiology and percutaneous coronary angioplasty(PCA) treatment, which quick-ly and effectively restore the blood flow to the area previously subjected to ischemia. Paradoxi-cally, the restoration of blood flow to the ischemic zone leads to a massive production of reactive oxygen species(ROS) which generate rapid and severe damage to biomolecules, generating a phenomenon called myocardial reperfusion injury(MRI). In the clinical setting, MRI is associated with multiple complications such as lethal reperfusion, no-reflow, myocardial stunning, and reperfusion arrhythmias. Despite significant advances in the understanding of the mechanisms accounting for the myocardial ischemia reperfusion injury, it remains an unsolved problem. Although promising results have been obtained in experimental studies(mainly in animal models), these benefits have not been translated into clinical settings. Thus, clinical trials have failed to find benefits from any therapy to prevent MRI. There is major evidence with respect to the contribution of oxidative stress to MRI in cardiovascular diseases. The lack- of consistency between basic studies and clinical trials is not solely based on the diversity inherent in epidemiology but is also a result of the methodological weak-nesses of some studies. It is quite possible that pharmacological issues, such as doses, active ingredients, bioavailability, routes of administration, co-therapies, startup time of the drug intervention,and its continuity may also have some responsibility for the lack- of consistency between different studies. Furthermore, the administration of high ascorbate doses prior to reperfusion appears to be a safe and rational therapy against the development of oxidative damage associated with myocardial reperfusion. In addition, the association with N-acetylcysteine(a glutathione donor) and deferoxamine(an iron chelator) could improve the antioxidant cardioprotection by ascorbate, mak-ing it even more effective in preventing myocardial reperfusion damage associated with PCA following AMI. | Jaime González-Montero Roberto Brito Abraham IJ Gajardo Ramón Rodrigo | 2018 | World Journal of Cardiology2018，10，9： | 56 |
| 2 | 结合珠蛋白2的变异促进脑卒中幸存者过早因心血管病死亡显示文摘结合珠蛋白(Haptoglobin,Hp)是一种急性期血浆蛋白,可保护组织免受氧化损伤。它存在2个变异等位基因(hp1/hp2),产生具有不同生化特性和不同功能的3种蛋白质异构体。先前研究发现, | Ij?s P Melkas S Saksi J Jula A Jauhiainen M Oksala N Pohjasvaara T Kaste M Karhunen PJ Lindsberg P Erkinjuntti T 刘莉 叶鹏 | 2017 | 中华高血压杂志2017，25，6： | 2 |
| 3 | The H19 non- coding RNA is essential for human tumor growth显示文摘 | Matouk IJ DeGroot N Mezan S | 2007 | PLoS One2007，2，9： | 1 |
| 4 | Association of the platelet Pl(A) polymorphism of glycoprotein Ⅱb/Ⅲa and the fibrinogen Bβ 448 polymorphism with myocardial infarction and extent of coronary artery disease显示文摘 | Ossei-Gerning N Wilson IJ | 1997 | Circulation1997，96，5： | 1 |
| 5 | The chemical form of mercury in fish显示文摘 | Harris H H Pickering IJ George G N | 2003 | Science2003，301，5637： | 1 |
| 6 | Matrix Metalloproteinase regulate neovascularization acting as pericelular fibrinolysins 显示文摘 | Hiraoka N Allen E Apel IJ | 2001 | Cell2001，95，1： | 1 |
| 7 | Evidence for a link between IGF-I and cancer显示文摘 | Pau IJ Jenkins N Stephen A | 2004 | Eur J Endocrino12004，151，1： | 1 |
| 8 | Environmental and genetic factors determine the level of NK activity of nude mice and affect their suitability as models for experimental metastasis显示文摘 | Hanna N Davis TW Fidler IJ | 1982 | Int J Cancer1982，30，3： | 1 |
| 9 | Screening for ovarian cancer : a pilot randomized controlled trial 显示文摘 | Jacobs IJ Skates SJ MacDonald N | 1999 | Lancet1999，353，9160： | 1 |
| 10 | Screening for ovarian cancer:a pilot randomised controlled trial显示文摘 | Jacobs IJ Skates SJ MacDonald N | | 0，，： | 1 |
| 11 | Fatigue as a predictor of sickness absence: results from the Maastricht cohort study on fatigue at work显示文摘 | Janssen N Kant IJ Swaen GM | 2003 | OccupEnvironMed2003，60，1： | 1 |
| 12 | Hexose-6-phosphate dehydrogenase confers oxo-reductase activity upon 11 beta-hydrox- ysteroid debydrogenase type 1 显示文摘 | ujalska IJ Draper N Michai|idou Z | 2005 | J Mol Endocrinol2005，34，3： | 1 |
| 13 | Sex differences in coagulation and fibrinolysis in subjects with coronary artery disease 显示文摘 | Ossei-Geming N Wilson IJ Grant PJ | 2008 | Thromb Haem- ost2008，79，： | 1 |
| 14 | CT screening for lung cancer: prevalence and incidence of mediastinal masses 显示文摘 | Henschk CI Lee IJ Wu N | 2006 | Radiology2006，239，2： | 1 |
| 15 | Novel polymorphisms in the promoter and 5'UTR regions of the human vascular endothelial growth factor gene显示文摘 | Brogan IJ Khan N Isaac K | 1999 | Hum Immunol1999，60，12： | 1 |
| 16 | Sereeing for ovarian cancer:a pilot randomised controlled tral显示文摘 | Jacobs IJ Skates SJ MacDonald N | 1999 | Lancet1999，353，9160： | 1 |
| 17 | The lectins: properties, functions and applications in biology and medicine显示文摘 | LIENER IE SHARON N GOLDSTEIN IJ | 1986 | Orlando:Academic Press1986，81，2： | 1 |
| 18 | Screening for ovarian canc- er : a pilot randomized controlled trial 显示文摘 | Jacobs IJ Skates SJ Macdonald N | 1999 | Lancet1999，353，9160： | 1 |
| 19 | Implementation of the DPM Monte Carlo code on a parallel architecture for treatment planning applica- tions显示文摘 | Tyagi N Bose A Chetty IJ | 2004 | Med Phys2004，31，： | 1 |
| 20 | Screening for ovarian cancer:a pilot randomised controlled trial显示文摘 | Jacobs IJ Skates SJ MacDonald N | 1999 | Lancet1999，353，9160： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员